Related Experiment Video

Updated: Oct 10, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.3K

HER2 in gastric adenocarcinoma: where do we stand today?

Khalil El Gharib1, Makram Khoury2, Hampig Raphael Kourie2

  • 1Department of Internal Medicine, Staten Island University Hospital, NY 10305, USA.

Personalized Medicine
|December 9, 2021
PubMed

Insights

HER2 inhibitors show promise in treating gastric cancer, a malignancy with high recurrence rates. Research is expanding to explore their efficacy in various stages and combinations with other agents.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • HER2 proto-oncogene is overexpressed in 10-30% of gastric adenocarcinomas.
  • HER2 overexpression is linked to poor prognosis and high recurrence rates in gastric cancer.
  • Targeting HER2 offers a therapeutic strategy for this malignancy.

Purpose of the Study:

  • To systematically review studies on HER2 inhibitors in gastric cancer.
  • To evaluate the efficacy and safety of HER2-targeted therapies.
  • To explore the use of HER2 inhibitors in different stages of gastric cancer.

Main Methods:

  • Systematic literature search of PubMed, Google Scholar, and clinicaltrials.gov.
  • Inclusion of 25 studies investigating HER2 inhibitors in gastric cancer.
  • Analysis of data from completed and ongoing clinical trials.

Main Results:

  • The ToGA trial established trastuzumab as a standard treatment for metastatic gastric cancer.
  • Multiple studies demonstrate the efficacy of various HER2 inhibitors.
  • Investigational use of HER2 inhibitors in locally advanced and locoregional gastric cancer is reported.

Conclusions:

  • Anti-HER2 therapies are effective and safe for gastric cancer treatment.
  • Growing evidence supports the role of HER2 inhibition in gastric cancer management.
  • Combination therapies involving HER2 inhibitors are under active investigation.
Keywords:
HER2TKIgastric cancerlapatinibpertuzumabtrastuzumab

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

351

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K